'MHRA Authorises Diabetes Drug Mounjaro (Tirzepatide) For Weight Management And Weight Loss' - UK Gov
Portfolio Pulse from Benzinga Newsdesk
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of Mounjaro (tirzepatide), a drug currently used for Type 2 diabetes, for weight loss and weight management in adults. The drug is now authorized for adult patients with a BMI of 30kg/m² or more, as well as those with a BMI between 27-30kg/m² who also have weight-related health problems. The authorization is based on the results of two international clinical trials, SURMOUNT-1 and SURMOUNT-2, which showed significant weight loss in patients treated with tirzepatide compared to those who took a placebo.
November 08, 2023 | 8:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly and Company, the manufacturer of Mounjaro (tirzepatide), could see a positive impact on its stock as the drug has been authorized for a new indication in the UK.
The authorization of Mounjaro for weight loss and weight management in the UK expands the drug's market, potentially leading to increased sales and revenue for Eli Lilly. This could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100